Treatment of advanced cervical cancer by combination of bleomycin and mitomycin-C
- 15 November 1980
- Vol. 46 (10) , 2159-2161
- https://doi.org/10.1002/1097-0142(19801115)46:10<2159::aid-cncr2820461009>3.0.co;2-m
Abstract
A combination of bleomycin and mitomycin-C, reported as extraordinarily effective in a previous clinical trial, was used to treat 20 patients with advanced cervical cancer. Seven partial remissions (35%) and one complete remission (5%) were observed. Six of the partial remissions were of short duration (less than four months); the only patient with complete remission was still alive without evidence of disease ten months after initiation of chemotherapy. Nonresponders had a mean survival time of 6.6 months and responders 8.0 months. The treatment results confirm some efficacy of the drug regimen, although in our hands it did not live up to the high expectations raised by others.This publication has 7 references indexed in Scilit:
- Effectiveness of a sequential combination of bleomycin and mitomycin-C on an advanced cervical cancerCancer, 1978
- MITOMYCIN-C, VINCRISTINE, AND BLEOMYCIN THERAPY FOR ADVANCED CERVICAL-CANCER1978
- The integration of chemotherapy into combined modality treatment of solid tumors: VIII. Cervical cancerCancer Treatment Reviews, 1977
- Low dose bleomycin and methotrexate in cervical cancerCancer, 1976
- Adriamycin and bleomycin, alone and in combination, in gynecologic cancersCancer, 1973
- Combination chemotherapy with bleomycin and methotrexate in recurrent and disseminated cervical carcinoma: A preliminary studyGynecologic Oncology, 1973
- Meaningful clinical classification of therapeutic responses to anticancer drugsClinical Pharmacology & Therapeutics, 1961